

1 **Researching COVID to enhance recovery (RECOVER) pregnancy study:**

2 **Rationale, objectives and design**

3 **Short Title: RECOVER Pregnancy Cohort Protocol**

4

5 Torri D. Metz^{1*}; Rebecca G. Clifton²; Richard Gallagher³; Rachel S. Gross⁴; Leora I. Horwitz⁵;
6 Vanessa L. Jacoby⁶; Susanne P. Martin-Herz⁷; Myriam Peralta-Carcelen⁸; Harrison T. Reeder⁹;
7 Carmen J. Beamon¹⁰; Marie-Abele Bind⁹; James Chan⁹; A. Ann Chang¹¹; Lori B. Chibnik⁹;
8 Maged M. Costantine¹²; Megan L. Fitzgerald⁵; Andrea S. Foulkes⁹; Kelly S. Gibson¹³; Nick
9 Güthe⁵; Mounira Habli¹⁴; David N. Hackney¹⁵; Matthew K. Hoffman¹⁶; M. Camille Hoffman¹⁷;
10 Brenna L. Hughes¹⁸; Stuart D. Katz¹⁹; Victoria Laleau²⁰; Gail Mallett²¹; Hector Mendez-
11 Figueroa²²; Vanessa Monzon⁶; Anna Palatnik²³; Kristy T.S. Palomares²⁴; Samuel Parry²⁵;
12 Myriam Peralta-Carcelen⁸; Christian M. Pettker²⁶; Beth A. Plunkett²⁷; Athena Poppas²⁸; Uma M.
13 Reddy²⁹; Dwight J. Rouse³⁰; George R. Saade³¹; Grecio J. Sandoval³²; Shannon M. Schlater³³;
14 Frank C. Scurba³⁴; Hyagriv N. Simhan³⁵; Daniel W. Skupski³⁶; Amber Sowles¹; Tanayott
15 Thaweethai⁹; Gelise L. Thomas³⁷; John M. Thorp, Jr.³⁸; Alan T. Tita³⁹; Steven J. Weiner²;
16 Samantha Weigand⁴⁰; Lynn M. Yee²¹; Valerie J. Flaherman²⁰ on behalf of the RECOVER
17 Initiative[^]

18

19 **Affiliations:**

20 ¹Department of Obstetrics and Gynecology, University of Utah Health Hospitals and Clinics, Salt
21 Lake City, UT, USA.

22 ²Biostatistics Center, The George Washington University, Washington, DC, USA.

23 ³Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New
24 York, NY, USA.

25 ⁴Department of Pediatrics, New York University Grossman School of Medicine, New York, NY,
26 USA.

27 ⁵Department of Population Health, New York University Grossman School of Medicine, New
28 York, NY, USA.

29 ⁶Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California,
30 San Francisco, San Francisco, CA, USA.

31 ⁷Department of Pediatrics, Division of Developmental Medicine, University of California San
32 Francisco, San Francisco, CA, San Francisco, CA, USA.

33 ⁸Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.

34 ⁹Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA.

35 ¹⁰Department of Maternal Fetal Medicine, WakeMed Health and Hospitals, Raleigh, NC, USA.

36 ¹¹Women's Health Research Clinical Center, University of California San Francisco, San
37 Francisco, CA, USA.

38 ¹²Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center,
39 Columbus, OH, USA.

40 ¹³Department of Obstetrics and Gynecology, The MetroHealth System, Cleveland, OH, USA.

41 ¹⁴Division Maternal Fetal Medicine, Trihealth Good Samaritan Hospital Maternal Fetal Medicine,
42 Cincinnati, OH, USA.

43 ¹⁵Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center: UH
44 Cleveland Medical Center, Cleveland, OH, USA.

45 ¹⁶Department of Obstetrics and Gynecology, Christiana Care Health System, Newark, DE, USA.

46 ¹⁷Department of Obstetrics & Gynecology, University of Colorado School of Medicine, Aurora,
47 CO, USA.

48 ¹⁸Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.

49 ¹⁹Department of Medicine, New York University School of Medicine, New York City, NY, USA.

50 ²⁰Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.

51 ²¹Department of Obstetrics and Gynecology, Northwestern University Feinberg School of
52 Medicine, Chicago, IL, USA.

53 ²²Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas
54 McGovern Medical School: The University of Texas Health Science Center at Houston John P
55 and Katherine G McGovern Medical School, Houston, TX, USA.

56 ²³Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI,
57 USA.

58 ²⁴Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Saint Peter's
59 University Hospital, New Brunswick, NJ, USA.

60 ²⁵Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.

61 ²⁶Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of
62 Medicine, New Haven, CT, USA.

63 ²⁷Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston,
64 IL, USA.

65 ²⁸Division of Cardiology, Brown University Warren Alpert Medical School, PROVIDENCE, RI,
66 USA.

67 ²⁹Department of Obstetrics and Gynecology, Columbia University, New York City, NY, USA.

68 ³⁰Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA.

69 ³¹Department of Obstetrics and Gynecology, The University of Texas Medical Branch at
70 Galveston, Galveston, TX, USA.

71 ³²Biostatistics Center, The George Washington University, Rockville, MD, USA.

72 ³³Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.

73 ³⁴Department of Medicine, Division of Pulmonary Allergy and Critical Care Medicine, University
74 of Pittsburgh, pittsburgh, PA, USA.

75 ³⁵Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh
76 School of Medicine, Pittsburgh, PA, USA.

77 ³⁶Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.

78 ³⁷Clinical and Translational Science Collaborative of Cleveland, Case Western Reserve
79 University, Cleveland, Ohio, Cleveland, OH, USA.

80 ³⁸Department of Obstetrics and Gynecology, UNC: The University of North Carolina at Chapel
81 Hill, Chapel Hill, NC, USA.

82 ³⁹Department of Obstetrics and Gynecology, Center for Women's Reproductive Health,
83 University of Alabama at Birmingham, Birmingham, AL, USA.

84 ⁴⁰Department of Obstetrics and Gynecology, Wright State University Boonshoft School of
85 Medicine, Dayton, OH, USA.

86

87 * Corresponding author

88 Email: torri.metz@hsc.utah.edu (TM)

89 ^Membership of the RECOVER Initiative is provided in the Acknowledgements.

90 Authorship has been determined according to ICMJE recommendations.

91 **Clinical Trials.gov Identifier:** Clinical Trial Registration: <http://www.clinicaltrials.gov>.

92 Unique identifier: NCT05172011

93 **Disclaimer**

94 The content is solely the responsibility of the authors and does not necessarily represent the
95 official views of the RECOVER program, the NIH or other funders.

96 **Funding**

97 This research was funded by the National Institutes of Health (NIH) Agreement OTA
98 OT2HL161841, OT2HL161847, and OT2HL156812 as part of the Researching COVID to
99 Enhance Recovery (RECOVER) research Initiative. This content is solely the responsibility of
100 the authors and does not necessarily represent the official views of the RECOVER Program or
101 the NIH.

102 **Competing interests**

103 Dr. Metz reports personal fees from Pfizer for her role as a medical consultant for a
104 SARS-CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for SARS-
105 CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for RSV
106 vaccination in pregnancy study, and grants from Gestvision for role as a site PI for a
107 preeclampsia study outside the submitted work. Dr. Horwitz reported serving as a member of
108 the National Academy of Medicine Committee on the Long-Term Health Effects Stemming from
109 COVID-19 and Implications for the Social Security Administration. Dr. Costantine reported
110 receiving grant support for work not related to this paper from Baxter International and Siemens
111 Healthcare and personal consulting fees not related to this paper from Progenity and Siemens
112 Healthcare.
113 The other authors state that they have nothing to disclose.

114

115 **Abstract**

116 **Importance:** Pregnancy induces unique physiologic changes to the immune response
117 and hormonal changes leading to plausible differences in the risk of developing post-acute
118 sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy
119 may also have long-term ramifications for exposed offspring, and it is critical to evaluate the
120 health outcomes of exposed children. The National Institutes of Health (NIH) Researching
121 COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to
122 evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER-
123 Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads.

124 **Methods:** RECOVER-Pregnancy cohort is a combined prospective and retrospective
125 cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19
126 pandemic and their offspring exposed and unexposed in utero, including single and multiple
127 gestations. Enrollment will occur both in person at 27 sites through the *Eunice Kennedy Shriver*
128 National Institutes of Health Maternal-Fetal Medicine Units Network and remotely through
129 national recruitment by the study team at the University of California San Francisco (UCSF).
130 Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in
131 the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated
132 screening tools, laboratory analyses and symptom questionnaires followed by more in-depth
133 phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in
134 utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and
135 other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be
136 collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later
137 analyses proposed by RECOVER and other investigators.

138 **Discussion:** RECOVER-Pregnancy will address whether having SARS-CoV-2 during
139 pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort
140 will also establish whether there are increased risks of adverse long-term outcomes among
141 children exposed in utero.

142 **Registration:** NCT05172024

143

144 Introduction

145 The disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
146 CoV-2), coronavirus disease 2019 (COVID-19), results in both short-term and long-term
147 sequelae, and many people with COVID-19 experience persistent health effects for months
148 beyond initial infection.¹⁻⁴ Thus, evidence regarding the post-acute sequelae of SARS-CoV-2
149 (PASC) or “long COVID” is urgently needed to guide clinical care and inform public health
150 policy.

151 Pregnant individuals may experience different long-term effects from COVID-19 than
152 non-pregnant individuals due to the immunomodulatory effects of pregnancy. In a publication
153 from the PRIORITY study consisting of pregnant individuals infected in 2020, 25% with COVID-
154 19 experienced prolonged viral symptoms 8 weeks after infection, with median time to resolution
155 of initial infection of 37 days.⁵ Data beyond those first 8 weeks are not available. Thus, it
156 remains unknown if there is a differential likelihood of PASC among individuals who contract
157 SARS-CoV-2 during pregnancy compared with non-pregnant adults.

158 In addition, the offspring of patients with COVID-19 during pregnancy may be at
159 increased risk of both short and long-term morbidity related to in utero exposure to SARS-CoV-
160 2, resulting from inflammation and vascular changes in the placenta⁶, as evidenced by
161 investigation of the effects of other viruses and in the setting of placental insufficiency. The
162 effects of SARS-CoV-2 on the health of pregnant individuals and their offspring may vary based
163 on SARS-CoV-2 variant, gestational age at infection, and maternal health and vaccination
164 status.⁷⁻¹² Existing data demonstrate that the Delta variant results both in the highest risk of
165 maternal critical illness and stillbirth, and in the most profound placental effects.^{7,8} Vaccination
166 has been found to be protective against both severe maternal COVID-19 and adverse
167 pregnancy outcomes, and may also influence the incidence of PASC in this population.⁹⁻¹¹

168 The National Institute of Health’s (NIH) RECOVER initiative has a unique opportunity to
169 study the post-acute sequelae of SARS-CoV-2 acquired in pregnancy. RECOVER-Pregnancy
170 will enroll maternal-child dyads to investigate the effects of SARS-CoV-2 acquired during
171 pregnancy on the long-term health of both the pregnant person and their offspring who were
172 exposed to SARS-CoV-2 in utero. We hypothesize that the incidence of persistent long-term
173 sequelae among pregnant people will vary from that of non-pregnant adults given the unique
174 changes in physiology, hormone levels, and inflammatory milieu in pregnancy. In addition, we
175 hypothesize that the offspring of individuals with SARS-CoV-2 infection in pregnancy will have
176 worse developmental outcomes when compared with unexposed offspring delivered over the
177 same time period. The overarching goal of RECOVER-Pregnancy is to describe PASC in
178 people who are infected with SARS-CoV-2 in pregnancy and examine the outcomes of their
179 offspring compared with children who were not exposed to SARS-CoV-2 in utero.

180 **Materials and Methods**

181 **Objectives**

182 RECOVER-Pregnancy cohort will enroll maternal-child dyads exposed and unexposed
183 to SARS-CoV-2 during pregnancy, with pregnant individuals participating in RECOVER-Adult
184 and offspring participating as the in utero exposed subgroup of RECOVER-Pediatric.

185 The broad objectives of both the RECOVER-Adult and RECOVER-Pediatric studies are
186 to: (1) characterize the incidence and prevalence of sequelae of SARS-CoV-2 infection; (2)
187 characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history,
188 and distinct phenotypes identified as sequelae of SARS-CoV-2 infection; (3) identify

189 demographic, social, and clinical risk factors for PASC and PASC recovery, and (4) define the
190 biological mechanisms underlying pathogenesis of PASC.

191 The study protocols for both RECOVER-Adult and RECOVER-Pediatric cohorts are
192 published separately.^{13,14} The RECOVER-Pregnancy cohort is summarized here. The primary
193 aims of the adult portion of the RECOVER-Pregnancy cohort include: (1) describing PASC
194 onset, symptoms and severity by comparing pregnant individuals with SARS-CoV-2 with
195 pregnant individuals without SARS-CoV-2, (2) characterizing risk factors for PASC onset,
196 symptoms and severity following SARS-CoV-2 infection during pregnancy by comparing
197 infected pregnant individuals with and without particular risk factors; and (3) evaluating if
198 contracting SARS-CoV-2 in pregnancy is associated with a differential risk of developing PASC
199 compared with non-pregnant individuals. The primary aims of the pediatric portion of the
200 RECOVER-Pregnancy cohort include characterizing the clinical manifestations of exposure to
201 SARS-CoV-2 infection during pregnancy on child physical health and behavioral and
202 developmental outcomes, by comparing children with and without maternal history of SARS-
203 CoV-2 infection during pregnancy.

204 **Study design and setting**

205 The NIH RECOVER study is a retrospective and prospective longitudinal meta-cohort
206 study design in which individuals with and without exposure to SARS-CoV-2 infection are
207 enrolled and followed over a maximum of 4 years. For RECOVER-Pregnancy, individuals with
208 and without SARS-CoV-2 infection during pregnancy will be included. Individuals with a SARS-
209 CoV-2 infection during pregnancy will be further classified as acute (infection within the past 30
210 days at the time of enrollment) and post-acute (more than 30 days since infection). The
211 RECOVER-Pregnancy cohort follows both the adult protocol and the part of the pediatric
212 protocol that is specific to in utero exposure to SARS-CoV-2.

213 Mother-child dyads for the RECOVER-Pregnancy cohort are recruited in person at 12
214 *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD)
215 Maternal-Fetal Medicine Units (MFMU) Network Centers which include 26 individual hospital
216 sites (encompassing community and academic hospitals) and remotely nationwide by the
217 University of California San Francisco (UCSF). A list of study sites can be obtained at
218 <https://recovercovid.org> or in Appendix 1. For participants recruited within the 26 individual
219 hospital sites of the MFMU Network, recruitment occurs among individuals who were enrolled in
220 the NICHD MFMU Gestational Research Assessments for COVID-19 (GRAVID) study^{15,16}, a
221 previously established cohort of individuals with and without SARS-CoV-2 during pregnancy
222 over the COVID-19 pandemic, and new prospective enrollments of individuals with and without
223 SARS-CoV-2 in pregnancy to encompass all variants of SARS-CoV-2. Study procedures for
224 participants recruited by NICHD MFMU Network sites will be completed through a combination
225 of remote survey assessments and in-person study visits. For those recruited remotely by the
226 study team at the UCSF, recruitment occurs among individuals who were enrolled in the
227 PRIORITY study, a previously established nationwide cohort of individuals with SARS-CoV-2
228 during pregnancy, as well as through new nationwide outreach including social media outreach,
229 referrals from the NIH RECOVER website, screening of the UCSF electronic health record and
230 from RECOVER-Adult cohort sites that are not also participating in the pregnancy cohort.
231 Participants recruited by UCSF will have study procedures such as anthropometric
232 measurements and specimen collections completed during home visits while surveys are
233 completed remotely. Individuals who are able to travel to UCSF may have study procedures
234 completed in person. Participants can only be enrolled once to avoid overlap in recruitment
235 across the RECOVER-Pregnancy sites.

236 **Study population**

237 Anyone with SARS-CoV-2 infection during pregnancy (defined as meeting World Health
238 Organization criteria¹⁷ for suspected, probable or confirmed SARS-CoV-2 infection), or with
239 documented lack of SARS-CoV-2 exposure during pregnancy, irrespective of pregnancy
240 outcome (loss, termination, or live birth) is eligible to enroll in RECOVER-Pregnancy (See
241 RECOVER-Adult protocol for detailed definition).¹³ The index date for infection is set as the date
242 of the first infection as determined by the date of a positive SARS-CoV-2 test, or set at 90 days
243 prior to antibody test date for those with positive antibodies who had an asymptomatic prior
244 infection. Individuals with SARS-CoV-2 in pregnancies resulting in a live birth are only eligible
245 for enrollment into one of the RECOVER pregnancy cohorts to facilitate co-enrollment of the
246 offspring in the in utero exposure part of the pediatric protocol. Individuals with pregnancies
247 resulting in pregnancy loss or termination are eligible to enroll at any adult cohort site.
248 Pregnancies and pregnancy outcomes for all adults in the RECOVER-Adult cohort over the
249 longitudinal follow-up period for RECOVER will also be recorded.

250 Those who had a pregnancy during the study enrollment window without SARS-CoV-2
251 infection are eligible for enrollment as uninfected controls. Uninfected controls must have no
252 reported history of SARS-CoV-2 infection, and be PCR negative and SARS-CoV-2 antibody
253 negative at the time of enrollment. For the pregnancy cohort, index date for the post-acute
254 uninfected controls is set at the date of delivery as the uninfected period of interest is the
255 pregnancy (e.g. controls should not have been infected during pregnancy). The recruitment
256 strategy seeks to have infected and uninfected individuals enrolled within the same time frame
257 to reduce potential effects of societal modifications during the pandemic which may also affect
258 neurodevelopment (e.g., social isolation, disruptions to education and childcare services,
259 financial parental stressors, etc).^{18, 19}

260 **Sample size**

261 Overall 2,300 adults with or without SARS-CoV-2 during pregnancy will be enrolled in
262 RECOVER-Pregnancy along with their offspring. Of the 2300 pregnant individuals enrolled in
263 the adult cohort, we plan to enroll 1867 infected with SARS-CoV-2 during pregnancy and 433
264 uninfected during pregnancy. Because pregnant participants are enrolling as dyads with their
265 offspring, we expect to enroll corresponding numbers of offspring exposed to SARS-CoV-2
266 during pregnancy and unexposed during pregnancy, allowing for variability due to factors such
267 as twins or multiple gestations and pregnancy loss. Of the adults enrolling in RECOVER-
268 Pregnancy with SARS-CoV-2 infections, we plan for 15% of them to be enrolled during a period
269 of acute infection (within 30 days of positive SARS-CoV-2 test).

270 For each comparison underlying the primary study objectives, we computed minimum
271 effect sizes detectable with 90% power and a type-1 error rate of 0.01, for the full target sample
272 sizes, as well as for only 25% of the overall cohort, as would be expected in a subgroup
273 analysis. These results are also reported in Table 1. The minimum detectable PASC risk
274 difference between pregnant participants with and without infection is 8.4% (15.8% in a 25%
275 subgroup), assuming the risk of developing PASC among participants with infection is 25%.
276 Assuming the prevalence of a given risk factor among pregnant participants with infection is
277 20%, and the risk of PASC in pregnant participants with infection who have the risk factor is
278 30%, the minimum detectable PASC risk difference between infected participants with and
279 without the risk factor is 9.5% (17.4% in a 25% subgroup). Assuming 25% of non-pregnant adult
280 participants are female and of reproductive age, the minimum detectable PASC risk difference
281 between SARS-CoV-2 infected participants with and without active pregnancy at infection is
282 4.7% (8.9% in a 25% subgroup). Finally, the minimum detectable difference in a continuous

283 biomarker or development score between offspring exposed to SARS-CoV-2 in utero and those
 284 unexposed during pregnancy is 0.206 standard deviations (0.413 in a 25% subgroup).
 285 Table 1. Sample size calculations for RECOVER-Pregnancy cohort (ES: effect size; RF: risk
 286 factor; RF+: risk factor positive; SD: standard deviation)

Comparison groups		Effect of interest	Assumptions	Min. Detectable ES (90% power, 0.01 type I error rate)	
				Full Sample	25% Subgroup
Pregnant infected (n=1867)	Pregnant uninfected (n=433)	Difference in risk of PASC	Risk of PASC in infected: 25%	8.4%	15.8%
Pregnant infected w/ RF (n=373)	Pregnant infected w/out RF (n=1494)	Difference in risk of PASC	Prevalence of RF: 20% Risk of PASC in infected, RF+: 30%	9.5%	17.4%
Pregnant infected (n=1867)	Non-pregnant infected reproductive	Difference in risk of PASC	Risk of PASC in non-pregnant infected: 25%	4.7%	8.9%

	age female (n=3283)		25% of non-pregnant infected are reproductive age females		
Infant exposed in-utero (n=1867)	Infant not exposed in-utero (n=433)	Difference in continuous biomarker or development score	Equal variances	0.206 SDs	0.413 SDs

287

288 Importantly, adult RECOVER-Pregnancy cohort participants will be included in the
289 planned primary analyses for RECOVER-Adult. Classification of adult pregnancy cohort
290 participants will vary depending on the analysis being performed. For example, an adult
291 participant who was uninfected during pregnancy will remain in the uninfected comparison
292 group for all analyses examining outcomes of the offspring, as the offspring will not be exposed
293 in utero. However, some of the enrolled adult pregnancy participants who were enrolled as
294 uninfected controls will acquire SARS-CoV-2 infection during the 4-year longitudinal follow-up
295 period. These participants will cross over to the infected group for the adult cohort, and will be
296 analyzed as infected in analyses assessing only the adult outcomes from that time period
297 forward, but their offspring will remain in the unexposed pediatric cohort. Thus, the RECOVER
298 Data Resource Center (DRC) will classify pregnant individuals with SARS-CoV-2 and their
299 offspring intentionally and separately for each analysis depending on the outcome being
300 examined.

301 **Study procedures**

302 Details of protocol development are included separately in study protocol manuscripts
303 for the RECOVER-Adult and RECOVER-Pediatric protocols.^{13,14} Development of the pregnancy
304 cohort study procedures and protocol occurred concurrently with the principal investigators for
305 the pregnancy cohort participating in the development of both the RECOVER-Adult and
306 RECOVER-Pediatric protocols. Study procedures for RECOVER-Adult are included in Figure 1.

307 Figure 1. Study procedures for RECOVER-Adult

308 A schematic of the relationship between pregnant individuals and their offspring, and the
309 distribution of acute and post-acute SARS-CoV-2 infection is included in Figure 2. For adult
310 participants, the pregnant cohort simply represents a predefined portion of the participants to
311 ensure that PASC following SARS-CoV-2 infection during pregnancy can be examined and to
312 examine differential effects when SARS-CoV-2 is acquired during pregnancy.

313 Figure 2. Schematic representation of planned enrollment for RECOVER-Pregnancy
314 including pregnant individuals (both with and without SARS-CoV-2 during pregnancy) and the
315 pediatric in utero exposure cohort. Acute infection is infection within the last 30 days and post-
316 acute infection is infection during pregnancy, but at a time that was more than 30 days from the
317 date of enrollment.

318 **Adult cohort**

319 The primary endpoint for the adult portion of the RECOVER-Pregnancy cohort mirrors
320 that of the larger adult cohort and is defined as the presence of incident or prevalent candidate
321 PASC symptoms over time. Secondary endpoints include biological and recovery trajectories
322 from SARS-CoV-2 infection, documentation of organ injury, and incident clinical diagnoses.

323 Tier 1 RECOVER adult study procedures consist of completion of symptom surveys for a
324 variety of PASC symptoms, height, weight and vital signs measurements, sit to stand and active
325 stand evaluations, a core set of laboratory studies, and biospecimen collection. Each Tier 2 test
326 is expected to be completed by approximately 30% of adult participants. Tier 2 testing can be
327 triggered by abnormal values or responses in Tier 1; in addition, tier 2 testing is triggered in a
328 randomly selected group of controls for comparison. Adult Tier 3 tests are both more invasive
329 and more time consuming. Each tier 3 test is expected to be performed in approximately 20% of
330 RECOVER participants. Participants may select to opt out of tier 2 and tier 3 tests without
331 withdrawing from the study.

332 Adult participants in the pregnancy cohort complete all of the Tier 1 study procedures as
333 defined in the adult cohort study design manuscript.¹³ Similarly, pregnancy cohort participants
334 are eligible for all of the Tier 2 and 3 study procedures with the exception of those detailed in
335 Table 2 as these were felt to have unacceptable risk to the participant, the fetus, or neonate for
336 this observational study. Similarly, triggers for some of the Tier 2 and Tier 3 tests have been
337 modified for those who are pregnant, postpartum (within 3 months of delivery date), or
338 breastfeeding as they would not be appropriate triggers during these time periods (Table 2). For
339 example, weight loss is not used as a test trigger for participants who are postpartum as weight
340 loss is anticipated postpartum.

341 Table 2. RECOVER-Adult study procedure modifications for pregnant, breastfeeding, or
342 postpartum individuals

Tier of Test	Adult Study Procedure Modification	Excluded Population	Justification for Modification

Tier 2	Volumetric non-contrast chest CT	Pregnant and <3 months postpartum	Unacceptable risk of radiation exposure to the fetus without direct benefit
Tier 2	Dual energy chest CT with contrast	Pregnant and <3 months postpartum	Unacceptable risk of radiation exposure to the fetus without direct benefit
Tier 3	MRI brain with gadolinium	Pregnant and <3 months postpartum	Unacceptable risk of gadolinium exposure for fetus and neonate (via breastmilk) with no direct participant benefit
Tier 3	Cardiac imaging with meta-iodobenzylguanidine (mIBG)	Pregnant and <3 months postpartum	Unacceptable risk of mIBG exposure for fetus and neonate (via breastmilk) with no direct participant benefit
Tier 3	Gastric emptying study	Pregnant and <3 months postpartum	Physiologic changes in pregnancy and early postpartum period with gut motility precludes accurate interpretation
Tier 3	Skin biopsy	Pregnant and <3 months postpartum	Invasive procedure without direct participant benefit
Tier 3	Muscle biopsy	Pregnant and <3 months postpartum	Invasive procedure without direct participant benefit

Tier 3	Lumbar puncture	Pregnant and <3 months postpartum	Invasive procedure without direct participant benefit
Tier 3	Tilt table testing	Pregnant and <3 months postpartum	Physiologic changes in pregnancy and early postpartum period with vasodilatory response precludes accurate interpretation
Tier 3	Full cardiopulmonary exercise testing	Pregnant and postpartum	Exercise tolerance differs during pregnancy and early postpartum period which precludes accurate interpretation
Tier 3	Bronchoscopy	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit
Tier 3	Right heart catheterization	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit
Tier 3	Upper endoscopy	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit

Tier 3	Colonoscopy with or without biopsy	Pregnant and postpartum	Invasive procedure and anesthesia without direct participant benefit
Tier 3	Cardiac imaging with meta-iodobenzylguanidine (mIBG)	Breastfeeding	Unacceptable risk of contrast exposure to neonate through breastmilk with no direct participant benefit
Tier 3	Gastric emptying study	Breastfeeding	Unacceptable risk of contrast exposure to neonate through breastmilk with no direct participant benefit

343

344

345

346

347

348

349

350

Pregnancy characteristics and pregnancy outcome data will be ascertained by maternal self-report through survey questions following the end of pregnancy. The survey questions will be validated through manual medical record abstraction at the NICHD MFMU Centers as medical record data for participants are readily available at the Centers. Pregnancy characteristics and outcome data that will be collected are included in Box 1. Additional important covariates that are being collected include trimester of pregnancy at time of infection, severity of infection and treatment for infection.

<p>Box 1. Pregnancy Outcome Data Ascertained for RECOVER-Pregnancy Cohort</p> <p>Estimated date of delivery</p> <p>Actual delivery date</p> <p>Number of prior pregnancies and outcome of prior pregnancies</p> <p>Number of fetuses in index pregnancy (either infected or uninfected with SARS-CoV-2)</p>

Live birth, stillbirth, miscarriage, or termination

Birthweight of fetus(es)

Gestational diabetes

Hypertensive disorder of pregnancy

Cesarean birth

Diagnosis of intraamniotic infection

Placental abruption

Administration of magnesium sulfate

Administration of antenatal corticosteroids

Postpartum hemorrhage

ICU admission during delivery hospitalization

351 **Pediatric in utero exposure cohort**

352 All children will participate in Tier 1 assessments, which include broad health screening
353 measures collected remotely via electronic surveys or telephone interviews, and Tier 2
354 assessments, which include more in-depth clinical assessments conducted either at in-person
355 visits or via videoconferencing. Tier 1 assessments occur at 12, 18, 24, 36 and 48 months of
356 age, and Tier 2 assessments occur at 24, 36 and 48 months of age (Figure 3).

357 Figure 3. Study assessment schedule for children enrolled in RECOVER-Pregnancy or the in
358 utero exposure cohort of RECOVER

359 Both Tiers 1 and 2 focus primarily on child developmental outcomes. Tier 1 includes
360 developmental screening across the domains of communication, gross motor, fine motor,
361 problem solving, and personal-social development using the Ages and Stages Questionnaire—
362 3rd Edition (ASQ-3)²⁰⁻²², social-emotional screening using the Ages and Stages Questionnaires:
363 Social-Emotional, 2nd Edition (ASQ:SE-2) and standardized screening for Autism Spectrum

364 Disorder (ASD) using the Modified Checklist for Autism in Toddlers Revised with Follow up
365 (MCHAT-RF)²³ (Figure 3). Child socioemotional and behavioral status will be assessed using
366 the Child Behavior Checklist (CBCL)²⁴. In addition, adaptive behavior, communication, cognitive
367 development, social emotional development, and physical development, will be assessed using
368 the Developmental Profile-4 (DP-4)²⁵ by direct caregiver interview (Figure 3).

369 Tier 2 assessments will include an evaluation of child development using the Bayley
370 Scales of Infant and Toddler Development, 4th Edition (Bayley-4)²⁶ and the Differential Abilities
371 Scales, 2nd Edition (DAS-II)²⁷. The Bayley-4 is a comprehensive developmental assessment tool
372 which will evaluate cognitive, language, and motor development for RECOVER. The DAS-II is a
373 comprehensive assessment that provides insight into how a child processes information and
374 problem-solving, related to verbal comprehension and nonverbal and spatial reasoning. Training
375 for administration of the Bayley-4, DAS-II and DP-4 will be conducted centrally by the
376 RECOVER Clinical Science Core (CSC) Neurocognitive Leadership Team, and videos of mock
377 administrations will be reviewed for all examiners to ensure validity of the administered exam
378 prior to performing any exams for the purposes of the RECOVER study.

379 In addition to the neurocognitive outcomes, broader child health outcomes are assessed
380 as well. Tier 1 surveys assess sociodemographic information, medical history and special health
381 care needs using items from the National Surveys of Children's Health²⁸, SARS-CoV-2 infection
382 history, related conditions (e.g., Multisystem inflammatory syndrome in children (MIS-C),
383 Postural Orthostatic Tachycardia Syndrome, and Long COVID diagnoses), COVID-19 testing
384 and vaccine history, COVID-19-related symptoms (acute and long-term), COVID-19 health
385 consequences (e.g., diet, physical activity, sleep, screen time, schooling, parenting) and social
386 determinants of health (e.g., early childhood experiences or stressors). Brief infant Sleep
387 Questionnaire (BISQ)²⁹ is also collected at 24 months of age.

388 Other Tier 2 assessments include anthropometric measurements, such as child weight,
389 length/height, and head circumference measured using well calibrated, quality instruments and
390 standardized techniques, to ultimately assess child weight trajectories, weight status and
391 cardiometabolic risk. A sample of blood will be obtained at 24 months for SARS-CoV-2 antibody
392 testing and central biobanking. Blood will be collected at 24 months by a trained and
393 experienced pediatric phlebotomist, or through remote at-home collection using a TASSO M20
394 device, which collects capillary blood using 4 volumetric sponges that each hold 17.5 μ L of blood
395 (70 μ L total). If using the Tasso M20 device, one sponge is used for SARS-CoV-2 spike and
396 nucleocapsid antibody testing and remaining sponges are banked for future use. If using in-
397 person phlebotomy, EDTA and SST tubes will be collected ensuring that the total blood volume
398 is less than 2 mL per kg of body weight.

399 **Data collection, management and quality assurance**

400 All data are collected through secure entry into a single instance of REDCap
401 created by the RECOVER DRC. Oversight of data and safety is provided by the RECOVER
402 Observational Safety Monitoring Board (OSMB) appointed by the National Institutes of Health
403 (NIH). The purpose of the OSMB is to assure independent review as to whether study patients
404 are exposed to unreasonable risk because of study participation, and to monitor study progress
405 and integrity. Data collection and quality assurance are further detailed in the RECOVER-Adult
406 cohort study design manuscript.¹³

407 **Statistical analysis**

408 The point prevalence of PASC symptoms, defined as the proportion of participants
409 reporting a symptom at a given follow-up time point among those remaining in RECOVER, will

410 be calculated across the follow-up period for participants with infection during pregnancy and
411 without infection during pregnancy, both overall and among those whose pregnancy has ended
412 (termination, miscarriage, or delivery). Odds ratios (ORs) adjusted for demographic factors will
413 be reported. A paradigm for identifying PASC cases will be developed in the broader adult
414 cohort as described in the RECOVER-Adult study design paper, and evaluated in the population
415 with SARS-CoV-2 infection during pregnancy along with alternative clinically-derived PASC
416 definitions.

417 Logistic regression analyses will be conducted to investigate associations between
418 cumulative incidence of PASC and clinical factors, demographics, and social determinants of
419 health among participants with infection during pregnancy, as well as comparing those infected
420 during pregnancy with infected non-pregnant reproductive age females. Sensitivity analyses
421 assessing the influence of pregnancy factors such as gestational age at infection, and timing of
422 follow-up visits relative to the end of pregnancy, will be considered.

423 Measures of child physical health and behavioral and developmental outcomes will be
424 summarized in the in utero exposure to SARS-CoV-2 cohort overall and by maternal infection
425 status during pregnancy. Two-sample, two-sided t-tests will be used to compare cross-sectional
426 means of continuous outcomes between groups, and chi-squared tests will be used to compare
427 categorical outcomes between groups. Multivariable linear and generalized linear regression
428 models will also be fit to adjust for relevant baseline factors that are different between groups.
429 For outcomes measured at multiple visits, trajectories will be modeled and compared using
430 linear and generalized linear mixed effects models.

431 **Safety and possible risks**

432 All RECOVER activities are approved by a single institutional review board (IRB), which
433 is the New York University IRB. All of the RECOVER-Pregnancy sites will establish reliance on

434 the single IRB for RECOVER. Any protocol modifications will be approved by the single IRB and
435 communicated with all RECOVER investigators and research staff by the CSC. Written informed
436 consent will be obtained for all participants by research personnel at participating RECOVER-
437 Pregnancy sites. Participants will have the opportunity to opt out of storage of specimens for
438 future use and for genetic analyses.

439 For both the pediatric and adult cohort portions of the pregnancy cohort, results from
440 laboratory testing and other tests performed as study procedures are monitored centrally by the
441 CSC, DRC, and the individual site PIs along with their research teams. For each lab result, the
442 research team determines if the result is normal and abnormal, and if abnormal whether it is
443 clinically actionable. For pregnant participants, many of the laboratory results fall outside of
444 established lab normal values; yet, are normal for pregnant individuals. Thus, thresholds for
445 clinical action differ for this special population and the need for clinical action will be determined
446 by the investigators at each site who are obstetricians or maternal-fetal medicine subspecialists.

447 If the neurodevelopmental test score or social emotional score falls in a range where
448 additional monitoring or referral are recommended, results of screening tests completed in Tier
449 1 (ASQ-3, ASQ:SE-2, MCHAT R/F) or assessment tests completed in Tier 2 (Bayley-4, DAS-II
450 and DP-4) will be provided to the caregiver of the participant with a recommendation to follow-
451 up with the child's primary health care provider. Ranges of concern will be determined by
452 psychologists and developmental-behavioral pediatricians, and standardized across the cohort.

453 **Discussion**

454 The NIH RECOVER-Pregnancy cohort will answer critical questions regarding the
455 incidence and trajectory of PASC following SARS-CoV-2 infection during pregnancy, and the
456 effects of in utero exposure to SARS-CoV-2 infection on offspring development. There are little

457 data regarding the incidence of PASC in a population who acquired SARS-CoV-2 during
458 pregnancy. Initial data from the PRIORITY Registry suggest persistence of symptoms among
459 pregnant individuals for weeks to months after SARS-CoV-2 infection.⁵ As pregnant individuals
460 have alterations in inflammatory response and hormone levels, and have been noted to have an
461 increased risk of severe or critical illness with SARS-CoV-2 infection, it is plausible that the rates
462 of PASC could be different in this group.^{4,30,31} Differences in the prevalence or symptoms of
463 PASC among those who acquire SARS-CoV-2 in pregnancy compared with non-pregnant
464 individuals could help with determination of the underlying pathophysiology of PASC.

465 Recent research suggests that being born during the pandemic is associated with lower
466 scores on neurodevelopmental screening than in historical controls; however, exposure to
467 SARS-CoV-2 infection alone was not associated with a difference from unexposed children
468 living through the pandemic.^{18,19} A large administrative database study by Edlow and colleagues
469 found an association between exposure to SARS-CoV-2 in utero and neurodevelopmental
470 diagnoses, but was limited by the possibility of ascertainment bias, because those exposed to
471 SARS-CoV-2 may have been more likely to be followed and referred.³² The RECOVER-
472 Pregnancy study will add to this available evidence by comparing children who were SARS-
473 CoV-2 exposed with contemporaneous unexposed controls, and following them longitudinally
474 over time. The RECOVER-Pregnancy study will also be able to examine for potential
475 differences in subsets of the population exposed to SARS-CoV-2 in utero, such as by trimester
476 of infection, or by maternal disease severity and treatments for SARS-CoV-2.

477 The design of the pregnancy cohort provides several strengths. Enrollment of maternal-
478 child dyads across the U.S. will increase generalizability of study results, enhance racial, ethnic,
479 and socioeconomic diversity, and enable collection of detailed information on both the mother
480 and the child to enable robust analyses. SARS-CoV-2 is known to have disproportionately
481 affected Black and Latino communities (especially early in the pandemic)^{33, 34}; thus, the

482 RECOVER-Pregnancy investigators are committed to reaching a diverse population for studying
483 the long-term effects of contracting SARS-CoV-2 in pregnancy. Individuals with pregnancies
484 across the time period of the COVID-19 pandemic will be included allowing for comparisons by
485 major SARS-CoV-2 variants, which are known to differentially affect pregnancy outcomes.^{7,8}
486 Allowing both in-person and remote assessments may help reach participants who could not
487 participate in one or the other types of study visits. Developmental and socioemotional-
488 behavioral screening and direct neurodevelopmental assessments will be performed by
489 centrally trained and certified study personnel.

490 Our study design has several important limitations. First, since study procedures are
491 extensive and require significant time, families who have less availability to attend study visits
492 may be less likely to enroll in or more likely to be lost to follow up. This could reduce the
493 generalizability of our results. In addition, because participants born at any time during the
494 pandemic are eligible for enrollment, participants born earlier in the pandemic will not be able to
495 be assessed for outcomes measured by the study at ages prior to their date of enrollment; thus,
496 we will have smaller sample sizes available for some of the pediatric outcomes.

497 We anticipate that further modifications to the protocol will be made as the COVID-19
498 pandemic evolves and the scientific community learns more about both PASC and the effects of
499 exposure to SARS-CoV-2 in utero on offspring. Nonetheless we have designed a rigorous study
500 to evaluate the effect of SARS-CoV-2 on maternal-child dyads and anticipate that it will
501 substantially further scientific understanding of the risks of contracting SARS-CoV-2 while
502 pregnant.

503 **Acknowledgements**

504 We would like to thank the National Community Engagement Group (NCEG), all patient,
505 caregiver and community representatives, and all the participants enrolled in the RECOVER
506 initiative.

507 Membership of the RECOVER Initiative is provided in a supplemental appendix file.

508 **Supporting Information**

509 The supporting information is provided in a supplemental appendix file.

511 References

- 512 1. Ballering AV, van Zon SKR, Hartman TCO, Rosmalen JGM. Persistence of somatic
513 symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet*
514 2022; 400: 452-61.
- 515 2. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.
516 *JAMA* 2020; 324(6): 603-05.
- 517 3. Bull-Otterson L. Post-COVID conditions among adult COVID-19 survivors aged 18-64
518 and \geq 65 years old – United States, March 2020-November 2021. *MMWR* 2021; 71:713.
- 519 4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms
520 and recommendations. *Nat Reviews Microbiology* 2023; 21: 133-146.
- 521 5. Afshar Y, Gaw SL, Flaherman VJ, et al. Clinical presentation of coronavirus disease
522 2019 (COVID-19) in pregnant and recently pregnant people. *Obstet Gynecol* 2020;
523 136(6):1117-25.
- 524 6. Schwartz DA, Avvad-Portari E, Babal P, et al. Placental tissue destruction and
525 insufficiency from COVID-19 causes stillbirth and neonatal death from hypoxic-ischemic
526 injury: a study of 68 cases with SARS-CoV-2 placentitis from 12 countries. *Arch Pathol*
527 *Lab Med* 2022; 146(6):660-76.
- 528 7. Seasely AR, Blanchard CT, Arora N, et al. Maternal and Perinatal Outcomes Associated
529 With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
530 CoV-2) Infection. *Obstet Gynecol* 2022;140(2):262-265.
- 531 8. Adhikari EH, SoRelle JA, McIntire DD, Spong CY. Increasing severity of COVID-19 in
532 pregnancy with Delta (B.1.617.2) variant surge. *Am J Obstet Gynecol* 2022;226(1):149-
533 151.
- 534 9. Stock SJ, Carruthers J, Calvert C, et al. SARS-CoV-2 infection and COVID-19
535 vaccination rates in pregnant women in Scotland. *Nat Med* 2022;28(3):504.
- 536 10. Hui L, Marzan MB, Rolnik DL, et al. Reductions in stillbirths and preterm birth in COVID-
537 19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal
538 outcomes. *Am J Obstet Gynecol* 2022; epub ahead of print.
- 539 11. Morgan JA, Biggio JR, Jr., Martin JK, et al. Maternal Outcomes After Severe Acute
540 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared
541 With Unvaccinated Pregnant Patients. *Obstet Gynecol* 2022;139(1):107-109.
- 542 12. Hughes BL, Sandoval GJ, Metz TD, et al. First- or second-trimester SARS-CoV-2
543 infection and subsequent pregnancy outcomes. *Am J Obstet Gynecol* 2022; epub
544 ahead of print.
- 545 13. Horwitz L, et al. National Institutes of Health REsearching COVID to Enhance Recovery
546 (RECOVER) Adult Cohort: Rationale, Objectives, and Study Design; submitted
547 concurrently.

- 548 14. Gross R, et al. National Institutes of Health REsearching COVID to Enhance Recovery
549 (RECOVER) Pediatric Cohort: Rationale, Objectives, and Study Design; submitted
550 concurrently.
- 551 15. Metz TD, Clifton RG, Hughes BL, et al for the National Institute of Child Health and
552 Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association of
553 SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality from Obstetric
554 Complications. *JAMA* 2022; 327(8):748-59.
- 555 16. Metz TD, Clifton RG, Hughes BL, et al for the National Institute of Child Health and
556 Human Development Maternal-Fetal Medicine Units (MFMU) Network. Association
557 Between Giving Birth During the Early Coronavirus Disease 2019 (COVID-19) Pandemic
558 and Serious Maternal Morbidity. *Obstet Gynecol* 2023; 141(1):109-118.
- 559 17. World Health Organization. WHO COVID-19: case definitions, updated in public health
560 surveillance for COVID-19, 22 July 2022. [https://www.who.int/publications/i/item/WHO-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1)
561 [2019-nCoV-Surveillance Case Definition-2022.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1). Accessed March 9, 2023.
- 562 18. Shuffrey LC, Firestein MR, Kyle MH, et al. Association of Birth During the COVID-19
563 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In
564 Utero Exposure to Maternal SARS-CoV-2 Infection. *JAMA Pediatr*. Published online
565 January 4, 2022:e215563. doi:10.1001/jamapediatrics.2021.5563
- 566 19. Huang P, Zhou F, Guo Y, et al. Association Between the COVID-19 Pandemic and
567 Infant Neurodevelopment: A Comparison Before and During COVID-19. *Front Pediatr*.
568 2021;9:662165. doi:10.3389/fped.2021.662165
- 569 20. Squires J, Bricker D. Ages & Stages Questionnaires®, Third Edition (ASQ®-3): A
570 Parent-Completed Child Monitoring System. Baltimore: Paul H. Brookes Publishing Co.,
571 Inc; 2009.
- 572 21. Squires J, Bricker D, Potter L. Revision of a parent-completed development screening
573 tool: Ages and Stages Questionnaires. *J Pediatr Psychol*. 1997;22(3):313-328.
- 574 22. Squires J, Twombly E, Bricker D, L P. Ages & Stages Questionnaires®, Third Edition
575 (ASQ®-3): Technical Report. Baltimore: Paul H. Brookes Publishing Co., Inc; 2009.
- 576 23. Robins DL, Casagrande K, Barton M, Chen CM, Dumont-Mathieu T, Fein D. Validation
577 of the modified checklist for Autism in toddlers, revised with follow-up (M-CHAT-R/F).
578 *Pediatrics*. 2014;133(1):37-45.
- 579 24. Achenbach TM and Rescorla LA. Manual for the ASEBA school-age forms & profiles: an
580 integrated system of multi-informant assessment. Burlington: University of Vermont,
581 Research Center for Children, Youth & Families; 2001.
- 582 25. Alpern GD. Developmental Profile 4 (DP-4). WPS. [https://www.wpspublish.com/dp-4-](https://www.wpspublish.com/dp-4-developmental-profile-4.html)
583 [developmental-profile-4.html](https://www.wpspublish.com/dp-4-developmental-profile-4.html). Accessed March 9, 2023.
- 584 26. Bayley N and Aylward GP (2019). Bayley Scales of Infant and Toddler Development (4th
585 Ed) technical manual. Bloomington, MN: NCS Pearson.
- 586 27. Elliott CD. Manual for the Differential Ability Scales, Second Edition. San Antonio, TX:
587 Harcourt Assessment; 2007.

- 588 28. Ghandour RM, Jones JR, Lebrun-Harris LA, et al. The design and implementation of the
589 2016 National Survey of Children's Health. *Matern Child Health J* 2018; 22(8):1093-
590 1102.
- 591 29. Sadeh A. A brief screening questionnaire for infant sleep problems: validation and
592 findings of an internet sample. *Pediatrics* 2004; 113(6): e570-7.
- 593 30. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long
594 COVID in non-hospitalized adults. *Nature Medicine* 2022; 28:1706-1714.
- 595 31. Saadedine M, El Sabeh M, Borahay MA, Daoud G. The influence of COVID-19 infection-
596 associated immune response on the female reproductive system. *Biology of*
597 *Reproduction* 2023; 108(2):172-182.
- 598 32. Edlow AG, Castro VM, Shook LL, Kaimal AJ, Perlis RH. Neurodevelopmental outcomes
599 at 1 year in infants of mothers who tested positive for SARS-CoV-2 during pregnancy.
600 *JAMA Netw Open* 2022; 5(6):e2215787.
- 601 33. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic
602 Disparities. *JAMA* 2020;323(24):2466-2467.
- 603 34. Burris HH, Mullin AM, Dhudasia MB, et al. Neighborhood Characteristics and Racial
604 Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
605 Seropositivity in Pregnancy. *Obstet Gynecol* 2022;139(6):1018-1026.

606

607

608

609

610

eCRF	Baseline	Time Point after index date															
		3m	6m	9m	12m	15m	18m	21m	24m	27m	30m	33m	36m	39m	42m	45m	48m
Enrollment	●																
Tier 1-2 Consent	●																
Identity	●																
Visit	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Comorbidities	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
COVID Treatment*	●																
Medications	●																
Change in Medications		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Demographics	●																
PASC Symptoms	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Vaccination Status	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Social Determinants of Health	●																
Social Determinants Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Alcohol/Tobacco	●																
Alcohol/Tobacco Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Disability	●																
Pregnancy	●																
Pregnancy Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Tier 1 office visit	●		●		●				●				●				●
Biospecimens	●	●	●		●				●				●				●
Lab Results	●	●	●		●				●				●				●
Tier 2/Tier 3 Tests		●															

* COVID Treatment not collected on people without infection

Legend

- Completed by research coordinator
- Completed by participant
- Completed by research coordinator with review/validation by participant

Figure 1




Figure 2




Figure 3